DITROPAN XL Drug Patent Profile

✉ Email this page to a colleague

When do Ditropan Xl patents expire, and when can generic versions of Ditropan Xl launch?

Ditropan Xl is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in DITROPAN XL is oxybutynin chloride. There are sixteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the oxybutynin chloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ditropan Xl

A generic version of DITROPAN XL was approved as oxybutynin chloride by TEVA PHARMS USA on November 14^th, 1988.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DITROPAN XL?
What are the global sales for DITROPAN XL?
What is Average Wholesale Price for DITROPAN XL?

Summary for DITROPAN XL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	22
Patent Applications:	1,693
Drug Prices:	Drug price information for DITROPAN XL
DailyMed Link:	DITROPAN XL at DailyMed

Drug patent expirations by year for DITROPAN XL

Recent Clinical Trials for DITROPAN XL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 2
Il-Yang Pharm. Co., Ltd.	Phase 2
Brigham and Women's Hospital	Phase 2

See all DITROPAN XL clinical trials

US Patents and Regulatory Information for DITROPAN XL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DITROPAN XL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DITROPAN XL

See the table below for patents covering DITROPAN XL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Mexico	9203733	DISPOSITIVO OSMOTICO PARA ADMINISTRAR CIERTAS DROGAS.	⤷ Sign Up
Australia	9052298		⤷ Sign Up
Norway	170834		⤷ Sign Up
United Kingdom	8334189		⤷ Sign Up
Italy	TO960427		⤷ Sign Up
Canada	2218714	FORME GALENIQUE CONTENANT DE L'OXYBUTYNINE (DOSAGE FORM COMPRISING OXYBUTYNIN)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DITROPAN XL

Recent Clinical Trials for DITROPAN XL

Make Better Decisions: Try a trial or see plans & pricing